Back in 2015 there was a great need to prognosticate in MS, predict high risk subjects from low risk, and select appropriate treatments based on disease activity in MS.
We envisaged back then that the neurofilament test (a neuronal protein that is released during damage) would be a robust marker for risk-stratification in MS, and introduced into our clinical practice at Barts, instead of it being the holy grail of research studies only.
Wind forward 5 years and the test now forms an integral part of our MS multi-disciplinary team decision making processes, and importantly allows us to treat those who would not normally have been eligible based simply on popular thinking.
We are firm believers of following the science, and the test was intuitive and made logical sense. The growing popularity of the test across the UK and abroad attests to others thinking in a similar way (below are the quarterly figures for the Barts neurofilament test).
‘For last year’s words belong to last years language’, and yet to drive this message forward myself and Prof Mark Freedman (University of Ottawa) are bringing together leading scientists and clinicians in neurofilament research to formulate a consensus in the applicability of the test and its function the across the world over at ACTRIMS-ECTRIMS 2020 meeting, Toronto.
If your centers are not currently offering this test they would all soon be. That is progress.
Happy New Year everyone!